Bangladesh’s Beximco signed off 2021 on a high launching the first generic version of Pfizer’s Paxlovid at about $186 for a five-day treatment course and claimed that it has ‘adequate capacities' for exports as well.
Within days of the US Food and Drug Administration’s emergency use authorization for Pfizer Inc.’s Paxlovid (nirmatrelvir and ritonavir tablets, co-packaged for oral use), Bangladesh’s Beximco Pharmaceuticals Ltd. announced that it had rolled out the first cut-price generic of the oral pill for the treatment of mild-to-moderate COVID-19.
Rabbur Reza, Beximco Pharmaceuticals' chief operating officer, told Scrip that the company had developed the product (available as Bexovid) “on...
The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.
In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.
Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
